profit from every $100 of sales.
$0$100
Zimmer Biomet Holdings
$103.21-1.29% today
+14.0% in 1 year
1-year low $79.581-year high $110.15
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $27.70 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Zimmer Biomet Holdings sold, what it kept, and what it did with the cash.
Sales went from $6.94 billion in 2022 to $8.23 billion in 2025, with $705 million of profit last year.
SalesProfit
Zimmer Biomet Holdings handed back 48% of the cash it generated last year.
Buybacks $487M$190M
Free cash flow 2025$1.4B
Bought back its own shares$487M
Paid as dividends$190M
Cash vs. debt$592M vs. $7.5B
Zimmer Biomet Holdings vs. similar companies
Zimmer Biomet Holdings grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Zimmer Biomet Holdings | 27.7× · Fair price | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Glaukos | No profit yet |
AI analysis
An AI analyst reads Zimmer Biomet Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 6,128 | 6,827 | 6,940 | 7,394 | 7,679 | 8,232 | |
| 4,303 | 4,867 | 4,920 | 5,310 | 5,487 | 5,738 | |
| – | – | 1,192 | 1,451 | 1,528 | 1,356 | |
| 982 | 1,798 | 1,495 | 2,220 | 2,251 | 2,217 | |
| -139 | 402 | 231 | 1,024 | 904 | 705 | |
| -0.67 | 1.91 | 1.10 | 4.88 | 4.43 | 3.55 | |
| 70.2% | 71.3% | 70.9% | 71.8% | 71.5% | 69.7% | |
| – | – | 17.2% | 19.6% | 19.9% | 16.5% | |
| -2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 24,418 | 23,456 | 21,066 | 21,497 | 21,365 | 23,092 |
| Cash | 802 | 378 | 376 | 416 | 526 | 592 |
| Total debt | 8,127 | 7,069 | 5,697 | 5,768 | 6,205 | 7,519 |
| Total liabilities | 12,218 | 10,790 | 9,039 | 9,009 | 8,889 | 10,386 |
| 12,194 | 12,661 | 12,020 | 12,481 | 12,468 | 12,698 | |
| 207 | 210 | 210 | 210 | 204 | 199 | |
| 0.3% | 3.4% | 2.5% | 5.5% | 5.3% | 4.4% | |
| -1.1% | 3.2% | 1.9% | 8.2% | 7.2% | 5.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,205 | 1,499 | 1,285 | 1,582 | 1,499 | 1,697 | |
| – | – | 218 | 395 | 357 | 277 | |
| – | – | 1,067 | 1,187 | 1,143 | 1,420 | |
| Dividends paid | 199 | 200 | 201 | 201 | 196 | 190 |
| – | – | 126 | 692 | 868 | 487 | |
| 74 | 76 | 105 | 100 | 101 | 90 |
Valuation
- 27.7×
- 12.2×
- –
- 1.1×
- 2.4×
- 13.8×
- 11.9×
- 7.3%
- 3.6%
- 1.1%
Profitability
- 69.7%
- 16.5%
- 8.6%
- 26.2%
- 5.0%
- 3.5%
- 5.8%
- 3.4%
- 6.2%
- 5.4%
Growth
- +6.1%
- –
- +28.9%
- +0.6%
- −1.3%
Financial health
- 3.2×
- 0.51
- 32.9%
- 4.4×
- 2.94
- 1.61
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 952
Top 30%of 884
Bottom 47%of 601
Bottom 34%of 886
Top 13%of 987
What analysts expect
- Average price target
- $97.90
- Range
- $83.00 – $120.00
- 7 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | 2.09 | 1.86 | +12.4% |
| Feb 10, 2026 | 2.42 | 2.38 | +1.7% |
| Nov 5, 2025 | 1.90 | 1.87 | +1.6% |
| Aug 7, 2025 | 2.07 | 1.98 | +4.5% |
| May 5, 2025 | 1.81 | 1.77 | +2.3% |
| Feb 6, 2025 | 2.31 | 2.30 | +0.4% |
| Oct 30, 2024 | 1.74 | 1.74 | +0.0% |
| Aug 7, 2024 | 2.01 | 1.99 | +1.0% |
1.1%of the share price, paid each year
On $1,000 invested$11a year at today's yield, before tax
+0.6%2020 to 2025
Raised–not every year
Paid per share, each year
$0.85 in 2015 → $0.96 in 2025
How safe it looks
27.0% of its profit
Room to growStretchedMore than it earns: 13.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
72Pass
Philip Fisher
49No pass
Peter Lynch
50No pass
Joel Greenblatt
15No pass
Charlie Munger
43No pass
Terry Smith
46No pass
Questions about Zimmer Biomet Holdings
Is Zimmer Biomet Holdings a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zimmer Biomet Holdings AI analysis
What does Zimmer Biomet Holdings do?
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It is in Medical - Devices, based in Warsaw, IN, United States, with 17,000 employees.
Does Zimmer Biomet Holdings pay a dividend?
Yes. At today's price the dividend is 1.1% a year, about 27% of its yearly profit. In 2025 it paid out $190 million in dividends.
Is Zimmer Biomet Holdings stock halal?
No. Zimmer Biomet Holdings does not pass our halal screen: its debt is 39% of its market value, at or above the 33% limit. How we check
How has Zimmer Biomet Holdings stock done over the past year?
Up 14.0% over the past twelve months, to $103.21. It traded between $79.58 and $110.15 and is 6.3% below its high.
Who are Zimmer Biomet Holdings's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Glaukos. The peers table on this page compares their profit, growth and price with Zimmer Biomet Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.